These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 37924135)

  • 21. Tumor mutational burden and efficacy of chemotherapy in lung cancer.
    Song J; Yan Y; Chen C; Li J; Ding N; Xu N; Bao H; Zhang X; Hong Q; Zhou J; Shao YW; Song Y; Tong L; Hu J
    Clin Transl Oncol; 2023 Jan; 25(1):173-184. PubMed ID: 35995891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KRAS mutation predict response and outcome in advanced non-small cell lung carcinoma without driver alterations receiving PD-1 blockade immunotherapy combined with platinum-based chemotherapy: a retrospective cohort study from China.
    Li Q; Zhou Q; Zhao S; Wu P; Shi P; Zeng J; Xiong X; Chen H; Kittaneh M; Bravaccini S; Zanoni M; Zhou C; Zhang J
    Transl Lung Cancer Res; 2022 Oct; 11(10):2136-2147. PubMed ID: 36386464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
    Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
    Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
    Patil T; Mushtaq R; Marsh S; Azelby C; Pujara M; Davies KD; Aisner DL; Purcell WT; Schenk EL; Pacheco JM; Bunn PA; Camidge DR; Doebele RC
    Clin Lung Cancer; 2020 May; 21(3):e191-e204. PubMed ID: 31859066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib.
    White MN; Piper-Vallillo AJ; Gardner RM; Cunanan K; Neal JW; Das M; Padda SK; Ramchandran K; Chen TT; Sequist LV; Piotrowska Z; Wakelee HA
    Clin Lung Cancer; 2022 May; 23(3):e210-e221. PubMed ID: 34887193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.
    Zhang B; Zeng J; Zhang H; Zhu S; Wang H; He J; Yang L; Zhou N; Zu L; Xu X; Song Z; Xu S
    Front Immunol; 2022; 13():974581. PubMed ID: 36159860
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Feng H; Xu H; Shi X; Ding G; Yan C; Li L; Jian Z; Yang X; Guo H; Li F; Zhang J; Ren X
    Front Biosci (Landmark Ed); 2023 Jul; 28(7):147. PubMed ID: 37525904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.
    Papadimitrakopoulou VA; Han JY; Ahn MJ; Ramalingam SS; Delmonte A; Hsia TC; Laskin J; Kim SW; He Y; Tsai CM; Hida T; Maemondo M; Kato T; Jenkins S; Patel S; Huang X; Laus G; Markovets A; Thress KS; Wu YL; Mok T
    Cancer; 2020 Jan; 126(2):373-380. PubMed ID: 31769875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histo-Molecular Factors of Response to Combined Chemotherapy and Immunotherapy in Non-Small Cell Lung Cancers.
    Marchal M; Leroy V; Behal H; Dansin E; Paris N; Bordier S; Humez S; Escande F; Gauvain C; Cortot AB
    Target Oncol; 2023 Nov; 18(6):927-939. PubMed ID: 37921939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non-small cell lung cancer with sensitive EGFR mutations.
    Zhang Y; Wang J; Yu Z; Ge H; Zhang LW; Feng LX
    Clin Transl Sci; 2021 May; 14(3):890-897. PubMed ID: 33382908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.
    Rulli E; Marabese M; Torri V; Farina G; Veronese S; Bettini A; Longo F; Moscetti L; Ganzinelli M; Lauricella C; Copreni E; Labianca R; Martelli O; Marsoni S; Broggini M; Garassino MC;
    Ann Oncol; 2015 Oct; 26(10):2079-84. PubMed ID: 26209642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer.
    Zhang J; Zhou N; Lin A; Luo P; Chen X; Deng H; Kang S; Guo L; Zhu W; Zhang J
    Cancer Immunol Immunother; 2021 Jan; 70(1):137-151. PubMed ID: 32653938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Investigation of PALB2 Mutation and Correlation With Immunotherapy Biomarker in Chinese Non-Small Cell Lung Cancer Patients.
    Zhang J; Tang S; Zhang C; Li M; Zheng Y; Hu X; Huang M; Cheng X
    Front Oncol; 2021; 11():742833. PubMed ID: 35087742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
    Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
    Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual Biomarker Combining DNA Damage Repair Gene Mutations and PD-L1 Expression for Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.
    Kim H; Lim DH; Kwon YS; Kim MA; Park KU
    Anticancer Res; 2023 May; 43(5):2343-2349. PubMed ID: 37097676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC.
    Mok TSK; Lopes G; Cho BC; Kowalski DM; Kasahara K; Wu YL; de Castro G; Turna HZ; Cristescu R; Aurora-Garg D; Loboda A; Lunceford J; Kobie J; Ayers M; Pietanza MC; Piperdi B; Herbst RS
    Ann Oncol; 2023 Apr; 34(4):377-388. PubMed ID: 36709038
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study.
    Willis C; Bauer H; Au TH; Menon J; Unni S; Tran D; Rivers Z; Akerley W; Schabath MB; Badin F; Sekhon A; Patel M; Xia B; Gustafson B; Villano JL; Thomas JM; Lubinga SJ; Cantrell MA; Brixner D; Stenehjem D
    Oncotarget; 2022; 13():257-270. PubMed ID: 35111281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.
    Masuda T; Imai H; Kuwako T; Miura Y; Yoshino R; Kaira K; Shimizu K; Sunaga N; Tomizawa Y; Ishihara S; Mogi A; Hisada T; Minato K; Takise A; Saito R; Yamada M
    Clin Transl Oncol; 2015 Sep; 17(9):702-9. PubMed ID: 25990507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.